AI 对冲基金 · 大师信号(存档)

Look at the rate of change and nothing else: TTM revenue growth went 29% -> 39% -> 48% -> 63% -> 85% -> 93% while operating margin went 11% -> 20% -> 33% -> 47% and gross margin lifted five points to 85%. Accelerating top line with doubling incrementals is the rarest setup there is — net margin at 55% on 93% growth means earnings are compounding at multiples of revenue, and there's no leverage on the balance sheet to blow me up. Yes, 143x earnings is a nosebleed, but a rich multiple on numbers that are still inflecting up is a buy; a cheap multiple on numbers rolling over is the trap. I size this big and I watch the second derivative like a hawk — the day growth decelerates at this price, the air pocket underneath is brutal and I'm out, not down.

This is plainly a fine business by the numbers I can see — 85% gross margins, operating margins that climbed from 1% to 47% in eight quarters, and revenue nearly doubling. That kind of operating leverage tells me customers aren't leaving and the company sets its own prices. But I'm being asked to pay 143 times earnings, roughly $402 billion for a company whose entire trailing profit is a rounding error against that price, and I've got no return on equity, no book value, no debt figures, and no free cash flow per share to check whether the earnings are real or whether management is allocating capital sensibly. At that multiple the next decade of flawless execution is already in the price, and I don't know enough about how durable a government-and-enterprise software franchise is ten years out to underwrite perfection. A wonderful business, perhaps — but I'll sit on my hands rather than pay a price that leaves no room for being wrong.

This is a genuine fast grower — revenue up 93% on a trailing basis with gross margins at 85% and operating margins climbing from 1% to 47% in eight quarters — so I'll give the business its due. But at 143 times earnings on a $402 billion market cap, the math implies roughly $2.8 billion of earnings on about $5 billion of revenue, which means you're paying something like 78 times sales for a company I'd have to explain with a paragraph, not a sentence. The other thing bothering me: net margin of 55% sits above the 47% operating margin, so a chunk of the 'earnings growth' is coming from something other than selling software, and margin expansion from 16% to 55% is a trick you can only pull once. I have no debt figure, no EPS, no book value and no free cash flow per share in front of me — when the price already assumes everything goes right and I can't check the balance sheet, that's how people lose money, not make it.

The business itself is remarkable and I won't pretend otherwise — 85% gross margins, operating margin climbing from 1% to 47% in eight quarters, and revenue growth accelerating to 93% instead of decaying. Then you look at the price: 143 times earnings on a $402 billion market cap, which backs into roughly $2.8 billion of earnings and something near 78 times revenue. Paying 78 times sales requires believing this company compounds at extraordinary rates for a decade with no competitor, no customer concentration problem, and no multiple compression — that is not investing, that is a wish. I'd also note the net margin of 55% exceeds the operating margin of 47%, meaning a meaningful slice of the earnings comes from below the operating line rather than the business, and they've given me no return on equity, no book value, and no free cash flow per share — so I'm asked to pay the highest multiple on the board while being shown the fewest of the numbers that matter.

At 142.93 times earnings, this price demands roughly seven to nine times the multiple a defensive investor should pay, and I have never in sixty years found a business whose future was certain enough to justify such an act of faith — even one earning a 55% net margin on revenue growing 93%. The margin of safety is not thin here; it is absent, and it is absent by a factor that no plausible earnings expansion can close. I am further denied the numbers I most want: no book value per share, no current ratio, no debt-to-equity, and no earnings-per-share record, so I cannot verify financial strength or the stability of earnings at all — only the improving margin trend, which is encouraging but is not a balance sheet. Where I cannot appraise value and can plainly see that the price capitalizes hope rather than demonstrated results, the verdict must be against the purchase.

The second derivative is going vertical here: TTM revenue growth went 34% → 38% → 50% across the last three prints, and it's happening alongside operating margin ripping from 11% to 14% to 17% and net margin from 13% to 20%. That's the rarest combination in this business — top-line acceleration and operating leverage landing in the same quarters — which means earnings are compounding at roughly double the revenue rate right now. Yes, 132x trailing looks absurd, but a trailing multiple on a company whose earnings power is doubling is a backward-looking number; the market is paying for the old trajectory, not the one printing today. I'd own it with real size and a hard stop, because the whole thesis is the rate of change — the day revenue growth stops accelerating, that multiple has nothing underneath it and I'm gone.

This is a fast grower, no question about it — revenue up 14% in fiscal 2024, 34% in 2025, and 50% in the latest twelve months, with net margin marching from 6% to 13% to 20% and gross margin picking up four points. That's the story checking out: sales growth turning into real operating leverage, quarter after quarter. But I'm being asked to pay 132 times earnings for it, and the only way that PEG works is if I assume triple-digit earnings growth keeps repeating — most of the recent jump is margin snapping back off a lousy 2024 base, not something you compound forever, and this is a chip company where one soft quarter (look at the 2025 Q2 dip to a 40% gross margin and negative operating margin) can take a big bite. On top of that, I have no EPS line, no book value, no debt-to-equity and no ROE in front of me, so I can't tell you whether the balance sheet would carry this story through a bad year — a fine business at a full price with half the checklist blank is a hold, not a buy.

The operating business is genuinely getting better — gross margin from 49% to 54%, operating margin from 8% to 17%, revenue up 50% — so I won't call it a bad business. But 132 times earnings on roughly $6 billion of profit means you're paying $843 billion for a semiconductor company at about 26 times revenue, and semiconductors are a capital-devouring, cyclical business where today's leader gets its head handed to it in the next cycle. Worse, they've handed me a sheet with no return on equity, no book value per share, no free cash flow, and no debt-to-equity — the four things I'd actually need to know whether this capital is compounding or being consumed, and in a fab-adjacent business that omission is not a rounding error. Improving margins into a mania do not justify a price that requires the next decade to go perfectly; I'll let someone else own the enthusiasm.

Semiconductors sit outside my circle — this is a business where the product you sell today is obsolete in three years and you must outspend a rival with a better fab just to stand still, which is the opposite of the candy bar that tastes the same in 2036. The operating record has genuinely improved — gross margin up four points to 54%, operating margin from 8% to 17%, revenue up 50% — but I'm handed no ROE, no debt-to-equity, no book value per share and, most tellingly, no free cash flow per share, so I cannot tell whether those earnings are real cash or capital being fed back into the machine. What I can see is the price: $843 billion at 132 times earnings, which requires everything to go right for a decade and leaves nothing for the owner if it doesn't. I'd rather own a fine business at a fair price than a fine business at a price that has already borrowed the next ten years of good news — no thanks, and I'll cheerfully be wrong.

At 842.6 billion of market value against earnings capitalized at 132 times, the price offers not a margin of safety but a margin of hope — the buyer today pays over eight times my outside limit of 15, and I have never found a growth forecast reliable enough to justify such a premium. The record itself is not the smooth ledger a defensive investor requires: operating margin swung to negative 0.02 as recently as 2025/Q2 and net margin has wandered between 0.06 and 0.20 over the ten periods shown, so even the demonstrated earning power is unsteady. Worse, I am shown no book value per share, no current ratio, and no debt-to-equity — the very figures on which financial strength is judged — and an investor who cannot inspect the balance sheet is speculating, whatever the business may be. Revenue rising 50 percent is the sort of fact that excites Mr. Market and should make the defensive buyer more cautious, not less; the enterprise may prosper, but at this price the shares are not an investment.

Revenue growth went 56% → 62% → 73% → 85% → 106% across the last five trailing periods — that is not a company decelerating off a blow-off top, that is a second-derivative reacceleration, and operating margin expanded right alongside it from 61% to 66%. Gross margin dipped to 61% in 2026/Q1 and has since rebuilt to a stable 75%, so whatever cost pressure the market was worried about is behind them and the incremental dollars are dropping through. And the market is paying 27.6x for that — a sub-30 multiple on triple-digit top-line growth with 66% operating margins means the price is discounting a sharp deceleration the numbers flatly refuse to deliver. That's the asymmetry: I'm long and I'm large, with the caveat that I have no leverage or EPS detail here, so the next print reversing the growth curve is my exit, not my reason to add.

This is a fast grower by any definition — trailing revenue is up 106% in the latest period, and it's not a one-off: the slowest stretch in this whole run was still 56% growth, and the trend has re-accelerated from 65% at fiscal 2026 year-end to 85% and now 106%. The part I like best is that the growth is dropping to the bottom line rather than being spent on the way down: gross margin at 75%, operating margin at 66%, and net margin at 62% — the best in the series — so earnings are compounding faster than sales. Pay 27.6 times earnings for a business growing anywhere near this rate and the PEG is well under half of one; that is a price that assumes a sharp slowdown that hasn't shown up in the numbers yet. Two things keep me from pounding the table: I have no debt figure, no book value, and no per-share earnings history here, so I'm taking the balance sheet on faith, and at $5.3 trillion this elephant has to keep dancing longer than any company ever has — but on the numbers in front of me, I'm paying a stalwart's multiple for a fast grower.

The economics here are the finest I've laid eyes on in a long while — 75% gross margins, 66% operating margins, 62% dropping to the bottom line, and revenue doubling over the trailing year. At 27.6 times earnings for that kind of profitability, I can't call the price absurd; the trouble is that a $5.3 trillion tag means the market has already paid me for a decade of me being right about a business whose customers could build their own chips or whose technology could turn over twice before then, and semiconductors have never sat comfortably inside my circle. The sheet in front of me shows no return on equity, no debt-to-equity, no book value per share and no free cash flow — four of the six things I most want to know — and I won't guess at them. Wonderful business, likely; understandable and durably moated at this price, I can't say from what I've been handed, so I'll stand aside rather than swing at a pitch I can't see clearly.

A business earning 75% gross and 66% operating margins while doubling revenue is not an ordinary business — and 27.6 times earnings for that is not a foolish price, so I won't call it bearish just because the number in front of it is five trillion dollars. But three of my five tests come back blank: no ROE, no book value per share, no free cash flow per share, no debt-to-equity. I am being asked to admire margins without being shown whether the capital behind them is compounding or whether the earnings are cash, and the 2026/Q1 quarter — gross margin collapsing to 61% and net to 43% before snapping back — tells me these margins are a condition, not a constitution. This is a semiconductor company whose extraordinary economics rest on a handful of customers choosing to keep spending at an unprecedented rate; I cannot underwrite that ten years out from this data, so it goes on the too-hard pile and I go neutral rather than pretend to knowledge I don't have.

A price of 5.26 trillion dollars against earnings capitalized at 27.6 times is already beyond the multiple I would pay for even a first-class enterprise, and the earnings themselves rest upon a 62% net margin — a figure so far outside ordinary commercial experience that to capitalize it as permanent is to pay twice for the same optimism. The record shown spans barely two years, with revenue swinging from 56% to 114% growth; that is not the demonstrated earnings stability a defensive investor requires, it is a boom, and booms are the worst moment to buy. I am furthermore given no book value per share, no current ratio, and no debt-to-equity figure, so the financial strength I insist upon before all else cannot be verified at all — and what cannot be verified must not be assumed. The business may well be excellent; the price offers no margin of safety whatever, and at these levels the buyer's protection rests entirely on the future behaving as hoped.

The whole engine inflected at once in the last two prints: TTM revenue growth re-accelerated from the 32-38% band that held through all of 2025 to 62-63% in 2026 Q1/Q2, gross margin went from 27-29% a year and a half ago to 36-38%, and operating margin compressed its loss from -50% to -25%. That's not drift, that's a business crossing over — volume scaling into a fixed cost base, which is exactly the shape that keeps surprising people to the upside for several quarters once it starts. What gives me pause is the other side of the ledger: a 37.7B cap on a company still running roughly -21% net margins means something on the order of fifty times revenue, so the market is not asleep on this story — it already believes in the trajectory, which is what caps the asymmetry rather than the trend. I'd own it and let the acceleration do the work, but I'm not backing up the truck at this price, and the gross margin tick from 38% to 36% is the first thing I'd watch for a crack.

On revenue this is a fast grower — 62% growth in the latest twelve months, accelerating from 38% in fiscal 2025, with gross margin climbing from 27% to 36% and the operating loss narrowing from -50% to -25%. That's a real business getting better, and I'll give it credit for that. But there are no earnings: the P/E is negative at -233, no EPS, no book value, no debt figure to check, so I can't compute a PEG at all — and the whole game is what you pay for earnings growth. You're being asked for $37.7 billion for a company that still loses about 21 cents on every dollar of sales, which means every penny of that price is a story about profits that haven't shown up yet. When the numbers improve this fast I'd rather wait for the first real quarter of profit and pay up then than guess at it now.

I understand rockets about as well as I understand a cattle auction in a foreign language — and what I can read here is a business that has never earned a dollar for its owners. Every period shown carries an operating loss, the best of them still negative 25 percent, with no return on equity, no book value per share, and no free cash flow to speak of; the gross margin has improved to 36 percent, which is real progress, but progress from losing a great deal to losing somewhat less. Meanwhile Mr. Market has hung a 37.7 billion dollar price tag on it — a price that demands flawless execution for a decade running, in a capital-hungry business where competitors have deeper pockets than anyone in it. I'd sooner own a fine business at a fair price than a promising one at a price that already assumes the promise was kept.

Ten periods of data and not one dollar of profit — net margin has been negative in every single one, the operating line runs 25 to 50 points underwater, and the P/E is a meaningless negative 233 because there are no earnings to divide into. Invert: what kills this? Paying $37.7 billion for a business that has never earned its cost of capital, has no measurable return on equity, no book value compounding, and no free cash flow to speak of — which means the capital comes from shareholders and lenders, not customers. I'll credit what's real: gross margin climbed from 27% to 36% and revenue grew 62%, so the thing is scaling and not a fraud. But a growing collection of losses capitalized at $37.7 billion requires me to believe something I can't underwrite from these numbers, and I'd rather miss the rocket than own it at this price.

The record before me shows not a single period of positive earnings — ten consecutive trailing-twelve-month periods of losses, with net margins ranging from -12% to -50% — and the market nonetheless assigns this enterprise $37.7 billion, a price that produces a negative P/E of -233 and therefore no earnings yield whatsoever to a defensive investor. Book value per share, current ratio, and debt-to-equity are all absent from the record, so I cannot even establish the financial strength that might excuse the absence of profits; what I cannot verify, I must not assume. I grant that gross margin has improved from 27% to 36% and revenue growth of 62% is genuine, but these are precisely the projections of future earning power for which I refuse to pay, and here one pays for them entirely. A price resting wholly on hope, with no demonstrated earnings and no visible margin of safety, is a speculation and not an investment.

This is the cleanest margin inflection I've seen in a mega-cap: gross margin has gone 58 → 68 and operating margin 47 → 60 across the last eight trailing periods, with the steepest leg in the two most recent quarters — net margin jumped 51 to 56 in a single step. Revenue growth wobbled to 20% in 2025/Q4 and everyone called the top; it has since reaccelerated to 35% and 36%, so the deceleration story the bears were building has already broken down. At 32x on 36% top-line growth with margins still expanding, the multiple says the market expects mid-cycle normalization, and the trend flatly disagrees — you're paying under 1x PEG for accelerating pricing power at a company earning 56 cents on the dollar. No leverage worry at these margins; the asymmetry is to the upside and I'd size this one up, with the caveat that I can't see the balance sheet or ROE lines here and the growth rate is the one thing that has already shown it can gap down.

This is a fast grower, plain and simple — revenue up 36% on the trailing twelve months and it's been running 30-42% for two years straight, so nothing is decelerating. Better yet, the margins are going the right way: gross margin 56% to 68%, operating 46% to 60%, net 40% to 56% since the 2024 full year, which means earnings are compounding a good deal faster than sales — roughly 70-80% year over year when you stack 36% revenue growth on top of that margin lift. Against that you're paying 32 times earnings, and a PEG in the neighborhood of 0.5 is the kind of arithmetic I built a career on; you're not paying up for the story, the story is already in the numbers. The one thing that keeps me from pounding the table is what I can't see — no debt-to-equity, no ROE, no book value here, and this is a capital-hungry cyclical where today's fat margins could be peak margins, so I'd want to look at the balance sheet before I sized it big.

Ten straight trailing periods of gross margin marching from 56% to 68% while revenue compounds 30-40% — that is not a commodity manufacturer, that is a toll bridge with pricing power, and the numbers say it plainly rather than requiring me to believe a story. Operating margin of 60% and net margin of 56% on a business this size means someone is paying whatever is asked, and 32 times earnings against that growth and that trajectory is a fair price, not a silly one. What stops me from pounding the table is that they have handed me no return on equity, no debt to equity, no book value, and no free cash flow per share — in a business that eats capital by the shovelful, the absence of the cash flow line is exactly the number I most want to see. Invert it: the way this fails is a capex binge financed with leverage into a cyclical air pocket where 68% margins revert to 45%, and the data given cannot tell me whether that is already brewing.

I can understand this one well enough: they manufacture the chips that everyone else designs, and the pricing power is written plainly in the numbers — gross margin has climbed from 56 cents on the dollar to 68 cents while revenue grew better than a third, and net margin went from 40% to 56%. A business that raises price and volume at the same time is not renting its position, it owns it; that is about as clear a toll bridge as you will find. At 32 times earnings against 36% revenue growth and still-widening margins, the price asks for continuation, not perfection — I'd rather pay that for a wonderful business than get a fair one cheap. What keeps me from thumping the table is what I cannot see: no return on equity, no debt-to-equity, no book value per share, and no free cash flow per share, which in a business this hungry for plants and equipment is exactly where I'd want to look hardest before committing serious money.

The enterprise itself is plainly prosperous — net margin of 0.56 on the latest twelve months, gross margin climbing from 0.56 to 0.68 across the record, and no period of loss anywhere in sight; that is demonstrated earning power of an uncommonly high order. But I am asked to pay 32 times earnings for it, better than twice the price a defensive investor should ever pay, and no book value per share, no current ratio, and no debt-to-equity figure are furnished to tell me what assets stand behind the price. A P/E of 32 for a cyclical manufacturer of capital-intensive goods capitalizes the continuation of an extraordinary boom, and margins that have expanded twelve points in two years are precisely the kind that revert. Excellent business, indefensible price — the margin of safety is not merely thin, it is absent, and absent that, the quality of the enterprise is no protection at all.

Invert it: what kills this? Margin collapse, leverage, or a silly price — and I see none of the three. Ten straight trailing periods with gross margins pinned at 67-69%, operating margins 45-49%, and net margins near 40% while revenue accelerates from 12% to 18% is not a fluke, it's a toll bridge with a moat around it, and the one-point gross margin drift is noise. At 27.6 times earnings for a business compounding revenue at 18% with forty cents of every dollar falling to the bottom line, you are paying a fair price for a great business, which is the only bargain left in a world this picked over. The blanks bother me — no ROE, no debt-to-equity, no free cash flow per share, and in a business now shoveling money into data centers I'd want to see the cash, not just the accruals — so I'll own it, not bet the farm on it.

This is a fast grower hiding inside a mega-cap: revenue is compounding 17-18% and actually accelerated from 15% last fiscal year, while net margin widened from 36% to 40% — that combination puts earnings growth somewhere in the mid-20s to low-30s, and you're paying 27.6 times for it. A PEG right around 1 on growth this visible is the kind of thing I'd buy; the story is simple enough to explain in a sentence, which is how I like them. Two things keep me from pounding the table: gross margin slipped a point to 68% as they build out capacity, and one quarter's 47% net margin looks like a one-timer, so I'd anchor on the 38-40% run rate. I also can't see debt/equity or book value here — Microsoft's balance sheet isn't what worries me, but I don't grade what I can't read, so call it a good story at a fair price rather than a gift.

Any business that keeps sixty-eight cents of gross profit and forty cents of net profit out of every sales dollar — while still growing revenue eighteen percent at a third of a trillion in sales — is a toll bridge, not a commodity, and the operating margin near forty-seven percent tells me nobody is competing the price away. At roughly 27.6 times earnings I'm paying a fair price for a wonderful business rather than the other way around; that's a 3.6% earnings yield attached to an owner-earnings stream that has been compounding, and I'll take that over a cigar butt. What bothers me is what isn't on the page: no return on equity, no debt-to-equity, no free cash flow per share, no book value — and in a period when everyone in this industry is pouring capital into data centers, I'd very much like to see how much cash actually reaches the owner after the spending. I'd own it and sleep fine for ten years, but I'm holding back a chunk of conviction until someone shows me the balance sheet and the cash flow statement.

The revenue inflection already happened and it's done inflecting — growth troughed at 12-13% in the middle of FY25, snapped back to 18%, and has now printed 18/17/18/18 for four straight quarters. That's a plateau, not an acceleration, and at 27.6x the market has clearly already paid for it. What actually has a slope right now is the wrong line: gross margin is down a point and operating margin has walked from 49% to 45% across the FY26 quarters, so operating income is growing slower than the top line even as revenue holds. Net margin at 40% flatters that, but with op margin falling it's coming from below the line, which I don't pay a premium for. Steady 18% growth, eroding operating leverage, full multiple — the trend and the price agree, and when they agree there's no asymmetry and no reason to have a position.

The enterprise itself is plainly prosperous — gross margins near 68%, operating margins in the mid-forties, and net margins of 36-40% held steady across every trailing period shown, with revenue advancing 12-18%. But I am asked to buy earnings, not admire them: at 27.61 times earnings the buyer receives an earnings yield of some 3.6%, well under half what my defensive standard of 15 times permits, and the premium rests on the continuation of that 18% growth rather than on anything already demonstrated. Worse, the record before me contains no book value per share, no current ratio, and no debt-to-equity figure, so I cannot apply my price-to-book test nor certify financial strength at all — and I do not grant an exemption from the balance sheet to a company merely because its income statement is handsome. A fine business bought at a speculative price is still a speculation; the margin of safety here is absent, and that fact alone settles the matter.

Revenue growth went 9% → 13% → 13% → 14% → 17% → 20% across the last six prints — that's not a base effect, that's a business re-accelerating, and it's happening while operating margin climbs from 10-11% to 13% then 14% and gross margin widens 47% to 52%. Growth accelerating into expanding margins is the single best setup there is, because the earnings line compounds both. At ~20x the market is paying for the old 11-12% grower with 11% operating margins — the multiple says trend continuation and the numbers say inflection, and that gap is where the money is. I'd size this up; the one thing I can't see is leverage (no D/E, no ROE, no cash flow per share) and the 31% net margin on the latest TTM looks juiced by something below the operating line, so I'm underwriting the 14% op margin, not the headline.

This is a fast grower that's actually speeding up: revenue growth went from 9% to 13% to 17% to 20% over six quarters, and operating margin climbed from 11% to 14% while gross margin widened three points. Growth on top of expanding margins means operating earnings are compounding well north of 20%, and you're being asked to pay 20.66x for it — that's a PEG comfortably under 1, which is the setup I spent a career hunting for. I'd temper my enthusiasm on two counts: net margin leaping from 11% to 31% in two quarters smells like a one-time item flattering that P/E, and there's no debt-to-equity, no book value, no free cash flow per share here, so I can't finish the balance-sheet part of the checklist. Even haircutting the earnings back to something like the 14% operating line, the price isn't pricing in the acceleration you can plainly see in the numbers.

The operating picture here is genuinely good — gross margin has climbed from 47 to 52 cents on the dollar, operating margin from a dime to fourteen cents, and revenue has reaccelerated to 20% on a base this large, which tells me somebody is charging more and spending better. But that 20.66 earnings multiple is a mirage: net margin leaping from 11% for the full year to 17% and then 31% in two quarters is not a business earning its way there, it's an accounting gain, and normalizing to the 11-13% this company actually earns puts the price nearer 45 or 50 times — a price that requires everything to go right for a decade. I'm also handed no return on equity, no debt-to-equity, no current ratio, no book value, and no free cash flow per share, which are precisely the numbers I'd want before owning a piece of a capital-hungry enterprise that builds warehouses and data centers. A fine business I don't get to inspect the balance sheet of, at a price that demands perfection, is a fine business I sit out.

The record shows a durable enterprise — positive operating and net margins in every one of the ten trailing periods shown, gross margin firming from 0.47 to 0.52, and revenue advancing at a steady 0.09 to 0.20 — and that is no small thing. But the defensive investor buys a balance sheet, not a margin trend, and here I am given no book value per share, no current ratio, and no debt-to-equity: three of my four tests cannot be applied at all, and I will not fill those blanks with imagination. What I can price is unappealing — 20.66 times earnings on a $2.77 trillion capitalization leaves no margin of safety by any conservative standard, and the latest period's 0.31 net margin against a 0.10-0.13 norm smells of a nonrecurring item that flatters that multiple rather than justifies it. A sound business at a price that already discounts its own success, with the balance sheet unexaminable: I stand aside.

A net margin of 31% sitting on top of a 14% operating margin is not earnings — it's an accounting event, and anyone paying 20.66 times that number is paying closer to 40 times the actual business. The operating trend is genuinely good: gross margin up three points, operating margin from 10% to 14%, revenue growth accelerating from 10% to 20%, which is rare at this size and I won't pretend otherwise. But there is no return on equity here, no book value per share, no debt-to-equity, and no free cash flow per share — the four numbers that tell you whether a colossus is compounding capital or eating it, all blank, in a business that has historically buried enormous capital spending. I don't know what I'm buying returns-wise, so it goes on the too-hard pile; I'd rather miss it than guess.

The inflection here is real and violent — TTM revenue growth swung from -34% in FY25 to +199% and +185% in the last two prints, gross margin climbed from 21% to 43%, and the operating margin loss has been cut from -14.7% to -5.5% over five quarters. That's operating leverage actually biting, and I don't short a business whose rate-of-change is improving on every line. But the price has already paid for it: a $5.1B cap on a revenue base so small that operating losses still run roughly five times sales means the market is discounting a decade of this curve, not the next quarter of it — and Q2's net margin already rolled back to -10.2% from +7.5% with growth ticking down. Trend and price agree, which means there's no asymmetry left to swing at; I'd rather own the second derivative when someone else is doubting it, not when the tape has priced perfection.

This isn't a fast grower, a stalwart, or a turnaround — it's a concept stock, and I can't run the PEG test at all because there are no earnings to divide into: the P/E is negative at -18.4 and operating margins run around -546% of sales, meaning the company spends roughly six dollars to bring in one. Revenue nearly tripling is real, but off a base so small that $5.1 billion of market value is paying for a story about quantum computing, not for profits; the one positive net margin quarter (+7.5% in 2026/Q1, with operating margin still deeply negative) came from something below the operating line, not from the business. Gross margin has drifted down from the low 50s to the low 40s, so the growth isn't even buying better economics, and I'm handed no debt/equity, no book value, and no cash flow per share — I genuinely don't know what the balance sheet looks like on a company that burns this hard. I never made money paying a big price for earnings that don't exist yet, and I'm not going to start here.

I don't know how to value a business whose operating margin is minus 546 percent — that means it spends about six and a half dollars to produce one dollar of sales, and it has done so in every period shown. There is no return on equity, no book value per share, no free cash flow and no earnings to speak of; the only positive net margins on the page (Q1 2025 and Q1 2026) sit alongside deeply negative operating margins, so they came from something other than selling a product, and I don't pay for that. Meanwhile the market is putting $5.1 billion on it while gross margin has slipped from 0.53 to 0.43 and revenue swung from four straight quarters of decline to a doubling — lumpy, not durable. This is outside my circle, priced for a future I can't underwrite, and I'd rather miss it than own it for ten years.

The P/E is negative at -18.4, which is no multiple at all but a statement that the owners are paying $5.1 billion for a stream of losses — implied earnings of roughly negative $277 million on revenue of about $27 million, since the net margin stands at -1024%. Operating margins run from -546% to -1470% across every period shown; the two quarters that show positive net margins (2025/Q1 at +28.95, 2026/Q1 at +7.52) sit alongside deeply negative operating margins, so the profit came from something other than the business, and such swings are the opposite of the earnings stability a defensive investor requires. Book value per share, current ratio, and debt-to-equity are all absent, so I cannot certify financial strength — but I need not, for no balance sheet could rescue a price set at roughly 190 times sales against a record of unbroken operating deficits. The 185% revenue growth is precisely the sort of projection Mr. Market pays for and the defensive investor declines to; there is no margin of safety here, only hope capitalized.

This thing burns roughly six and a half dollars of operating cost for every dollar it takes in — an operating margin of minus 546 percent — and the market is paying about 190 times revenue for the privilege, on a $5.1 billion cap against a revenue base you could fit in a rounding error. The two quarters showing positive net margin, plus 7.5 and plus 29, sit next to operating margins of minus 546 and minus 1,470; that is not earnings, that is a mark on some non-operating instrument, and dressing up a loss that way tells you what kind of numbers you're reading. Gross margin has gone backwards from 0.53 to 0.43 while they were supposedly scaling, and there is no return on equity, no book value per share, no free cash flow and no debt figure to examine — because there is nothing there to compound; the capital comes from selling paper to hopeful people. Revenue tripling off a trivial base after five straight quarters of decline doesn't fix any of it: to own this you must believe a story about the far future, and I have made my money believing arithmetic instead.